Evolus Announces Inducement Grants for New Chief Marketing Officer
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a
focus on building an aesthetic portfolio of consumer brands, today
announced that the Compensation Committee of the Board of Directors
approved the grant of stock options to purchase an aggregate of
83,555 shares of Evolus common stock and 63,358 restricted stock
units (RSUs) to Tomoko Yamagishi-Dressler, the company’s new Chief
Marketing Officer. The stock options and RSUs were granted as of
August 21, 2023 and were approved in accordance with Nasdaq Listing
Rule 5635(c)(4) as a material inducement to the employee’s
acceptance of employment with the company.
The stock options have an exercise price of $9.40 per share, the
closing price of Evolus’ common stock on August 21, 2023, the last
trading day prior to Ms. Yamagishi-Dressler’s start date. The stock
options have a 10-year term and vest over 4 years, with 25% of the
number of shares subject to the option vesting on each annual
anniversary of Ms. Yamagishi-Dressler’s first day of employment.
The RSUs vest 25% on each annual anniversary of Ms.
Yamagishi-Dressler’s start date. Both the stock options and the
RSUs are subject to acceleration in certain events including
certain terminations or upon certain terminations in connection
with a change in control of Evolus. The stock options and RSUs were
granted outside of Evolus’ 2017 Omnibus Incentive Plan.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving
the aesthetic neurotoxin market for the next generation of beauty
consumers through its unique, customer-centric business model and
innovative digital platform. Our mission is to become a global,
multi-product aesthetics company based on our flagship product,
Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin
dedicated exclusively to aesthetics and manufactured in a
state-of-the-art facility using Hi-Pure™ technology. Evolus is
expanding its product portfolio having entered into a definitive
agreement to be the exclusive U.S. distributor of Evolysse™, a line
of five unique dermal fillers currently in late-stage development.
Visit us at www.evolus.com, and follow us on LinkedIn, Twitter,
Instagram or Facebook.
Jeuveau® and Evolysse™ are trademarks of Evolus, Inc. Hi-Pure™
is a trademark of Daewoong Pharmaceutical Co, Ltd.
version on businesswire.com: https://www.businesswire.com/news/home/20230823557785/en/
Investor Contact: David K. Erickson
Vice President, Investor Relations Tel: 949-966-1798 Email:
Media Contact: Email:
Historical Stock Chart
From Feb 2024 to Mar 2024
Historical Stock Chart
From Mar 2023 to Mar 2024